Alessandro Di Federico
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Alessandro Di Federico
Jun 21, 2024, 04:15 |
Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 20, 2024, 12:07 |
Insight
Research into why some respond to TKIs better than others - Oncogene Cancer Research
Oncogene Cancer Research recently shared a post on X: "Worth reading this deep dive into…
Jun 9, 2024, 16:53 |
Blog
Alessandro Di Federico: Lovely days at ASCO2024
Alessandro Di Federico, Medical Oncologist and PhD student at University of Bologna, shared a post…
May 29, 2024, 09:25 |
Insight
Biagio Ricciuti: The association of automatically extracted body composition metrics with IO efficacy in mNSCLC
Biagio Ricciuti, recently posted on X: "Out in JAMA Oncology! Our effort to determine the…
Jan 19, 2024, 14:06 |
Insight
Mark Awad: Our group's effort to elucidate mechanisms of resistance to PD-1 immunotherapy in lung cancer
Mark Awad, Director of Clinical Research, Associate Professor of Thoracic Oncology at the Dana-Farber Cancer…
All:
5
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube